6 November 2013
Endomagnetics Ltd, the UCLB spinout company that is developing a portfolio of products to improve the standard of breast cancer management, has been named as a winner of the inaugural Nanomedicine Award at BIO-Europe 2013 in Vienna.
The Nanomedicine Award has been organised by the European Technology Platform for Nanomedicine (ETPN), together with the EU funded consortium NANOMED2020 and aims to honour the best international nanomedicine innovations.
The Award Review Board consisted of a panel of respected pharma industry specialists. “A global consensus was reached to deliver the award to Endomagnetics for its outstanding development,” stated a spokesperson for the board.”
In accepting the award, CEO of Endomagnetics Dr Eric Mayes said, “Endomagnetics is very honoured to have been selected for an inaugural Nanomedicine Award, particularly given the global candidature and great promise of this convergent industry. This award enhances the medtech facet of nanomedicine and increases the visibility of our SentiMag® and Sienna+® system to potential partners as we develop further across the nanomedicine field.”
Dr Steven Schooling, who represents UCLB’s interests on the board of Endomagnetics further noted, “It is great to see the continuing commercial progress of Endomagnetics being recognised with this high profile Nanomedicine Award.”
UCLB is a leading technology transfer company that supports and commercialises research and innovations arising from UCL, one of the UK’s top research-led universities.
UCLB has a successful track record and a strong reputation for identifying and protecting promising new technologies and innovations from UCL academics. It invests directly in development projects to maximise the potential of the research and manages the commercialisation process of technologies from the laboratory to market.
UCLB supports UCL’s Grand Challenges of increasing UCL’s positive impact on and contribution to Global Health, Sustainable Cities, Intercultural Interaction and Human Wellbeing.
For further information, please visit: www.uclb.com